ACTG1 facilitates proliferation and epithelial-mesenchymal transition-mediated metastasis via COL21A1 in gastric cancer.
Gastric cancer (GC) remains a lethal malignancy with limited therapeutic options.
APA
Li S, Lan B, et al. (2026). ACTG1 facilitates proliferation and epithelial-mesenchymal transition-mediated metastasis via COL21A1 in gastric cancer.. iScience, 29(2), 114666. https://doi.org/10.1016/j.isci.2026.114666
MLA
Li S, et al.. "ACTG1 facilitates proliferation and epithelial-mesenchymal transition-mediated metastasis via COL21A1 in gastric cancer.." iScience, vol. 29, no. 2, 2026, pp. 114666.
PMID
41704754
Abstract
Gastric cancer (GC) remains a lethal malignancy with limited therapeutic options. We investigated the role of γ-actin (ACTG1) in GC progression. Bioinformatics analyses revealed that ACTG1 is upregulated in GC tissues and correlates with poor patient prognosis. Functionally, the knockdown of ACTG1 suppressed GC cell proliferation and metastasis in both and models. Transcriptomic sequencing identified COL21A1 as a key downstream effector, and KEGG analysis indicated involvement in epithelial-mesenchymal transition (EMT). Critically, overexpression of COL21A1 rescued the inhibitory effects of ACTG1 knockdown on proliferation, migration, and EMT. These findings demonstrate that the ACTG1/COL21A1 axis promotes GC progression by regulating EMT, highlighting its potential as a therapeutic target for patients with GC.
같은 제1저자의 인용 많은 논문 (5)
- Complications Following Subpectoral Versus Prepectoral Breast Augmentation: A Meta-analysis.
- Spasticity Treatment Beyond Botulinum Toxins.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Heterogeneous associations between molecular subtypes of small cell lung cancer and survival prognosis: a systematic review highlighting knowledge gaps.
- In silico design of the multi-epitope vaccine for lung adenocarcinoma based on hub gene-derived neoantigens.